Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica™ System.
Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity in all Life Sciences areas: research, therapeutics, and all the “omics”.
Improve health by offering high precision genetic analysis solutions to researchers and clinicians worldwide
At Stilla Technologies, we continuously innovate and evolve technologically toward better human health outcomes. Our global team with multidisciplinary expertise shares a passion to develop new products for advanced genetic testing and analysis. Our expertise spans from microfluidics and chemistry to molecular biology and computer science.
Our product, the Naica™ System, has been adopted by researchers & clinicians around the world to develop a wide range of genetic tests and molecular biology assays – including, but not limited to, liquid biopsy tests for cancer diagnostics, infectious diseases, prenatal testing, and GMO detection.
Fundraising 20 million
Stilla Inc. opened
Invention of the technology at Ecole Polytechnique France
China & South East Asia
Hungary, Slovakia, Poland & Czech Republic